Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could rival MRI for prostate cancer detection

NCT ID NCT05220501

Diagnosis Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new, high-resolution ultrasound (micro-ultrasound) can find aggressive prostate cancers as well as MRI does during biopsy. Over 800 men with suspected prostate cancer were randomly assigned to one of three biopsy guidance methods. The goal was to see which approach best detects cancers that need treatment, potentially offering a simpler and cheaper alternative to MRI.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

804 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men indicated for prostate biopsy due to elevated Prostate Specific Antigen and/or abnormal Digital Rectal Examination * No history of prior prostate biopsy * No history of genitourinary cancer, including prostate cancer * 18 years or older * No contraindications to biopsy * No contraindications to mpMRI * No history of mpMRI for clinical investigation of prostate cancer within 12 months prior to screening and enrollment in the study Exclusion Criteria: * History of prior prostate biopsy * History of genitourinary cancer, including prostate cancer * Contraindications to biopsy * Contraindications to mpMRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, 29572, United States

  • Centre Hospitàlier Martigues, Hôpitaux de Provence

    Martigues, France

  • Hopital Delta

    Brussels, Belgium

  • Humanitas

    Milan, Italy

  • Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4, Canada

  • Hôpital du Sacré-Cœur de Montréal

    Montreal, Quebec, H4J 1C5, Canada

  • ICUA Madrid

    Madrid, Spain

  • Johns Hopkins

    Baltimore, Maryland, 21205, United States

  • L'Institut Mutualiste Montsouris

    Paris, France

  • Madrid ROC

    Madrid, 28010, Spain

  • Ordensklinikum Elisabethinen

    Linz, Austria

  • ProUro

    Berlin, Germany

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N3M5, Canada

  • UCLA

    Los Angeles, California, 90095, United States

  • University Health Network - Princess Margaret Hospital

    Toronto, Ontario, M5G 2C4, Canada

  • University of Alberta

    Edmonton, Alberta, T6G1Z1, Canada

  • University of Brandenburg

    Brandenburg an der Havel, Brandenburg, Germany

  • University of Florida Health

    Gainsville, Florida, 32611, United States

  • University of Magdeburg

    Magdeburg, Saxony-Anholt, 39120, Germany

  • University of Tuebingen

    Tübingen, Germany

  • Urologica Clinica Bilbao

    Bilbao, Spain

  • Yale University

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.